Authors' objectives: 1. Identify properties of screening tests for GDM. 2. Evaluate benefits and harms of screening for GDM. 3. Assess the effects of different screening and diagnostic thresholds on outcomes for mothers and their offspring. 4. Determine the benefits and harms of treatment for a diagnosis of GDM.

Authors' recommendations: While evidence supports a positive association with increasing plasma glucose on a 75 g or 100 g oral glucose tolerance test and macrosomia and primary cesarean section, clear thresholds for increased risk were not found. The 50 g oral glucose challenge test has high NPV but variable PPV. Treatment of GDM results in less preeclampsia and macrosomia. Current evidence does not show that treatment of GDM has an effect on neonatal hypoglycemia or future poor metabolic outcomes. There is little evidence of short-term harm from treating GDM other than an increased demand for services. Research is needed on the long-term metabolic outcome for offspring as a result of GDM and its treatment, and the "real world" effects of GDM treatment on use of care.

Project Status: Completed

Year Published: 2012

URL for published report: http://www.effectivehealthcare.ahrq.gov/ehc/products/397/1295/EvidenceReport210_GestationalDiabetes_FinalReport_20121019.pdf

URL for additional information: http://www.ahrq.gov/clinic/tp/gdmexuptp.htm

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: Agency for Healthcare Research and Quality

Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;

Contact Name: martin.erlichman@ahrq.hhs.gov

Contact Email: martin.erlichman@ahrq.hhs.gov

Copyright: Agency for Healthcare Research and Quality (AHRQ)